1-9 of 9
Michał Kwiatek
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Pirtobrutinib vs bendamustine plus rituximab (BR) in patients with CLL/SLL: First results from a randomized phase III study Examining a non-covalent BTK inhibitor in untreated patients

Free
Wojciech Jurczak, Michal Kwiatek, Jaroslaw Czyz, Ederson de Mattos, Ki-Seong Eom, Alexander Egle, Anna Panovská, Zhanet Grudeva-Popova, Hsuan-Jen Shih, Luis Felipe Casado Montero, Paolo Sportoletti, Vu Minh Hua, James D'Olimpio, Shinsuke Iida, Rodrigo Ito, Katherine Bao, Anne Fink, Weiji Su, Amy Ruppert Stark, Alejandro Levy, Tomasz Wrobel
Journal: Blood
Blood (2025) 146 (Supplement 2): LBA-3.
https://doi.org/10.1182/blood-2025-LBA-3
Published: 2025
Journal Articles

Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, plus R-CHOP in patients (Pts) with previously untreated aggressive B-cell lymphoma (a-BCL): 24-month efficacy Results

Free
Grzegorz Nowakowski, Marc Hoffmann, Javier Munoz, Jason Westin, Alejandro Martin Garcia-Sancho, Michal Kwiatek, Wojciech Jurczak, Maria Bouzani, Muhamad Alhaj Moustafa, Akshay Sudhindra, Argyrios Gkasiamis, Arpankumar Patel, Floriane Boucaud, Serena Perna, Theodoros Vassilakopoulos
Journal: Blood
Blood (2025) 146 (Supplement 1): 476.
https://doi.org/10.1182/blood-2025-476
Published: 2025
Journal Articles

Bexobrutideg (NX-5948), a novel Bruton's tyrosine kinase (BTK) degrader, demonstrates rapid and durable clinical responses in Relapsed/Refractory chronic lymphocytic leukemia (CLL): New and updated findings from an ongoing Phase 1a/b trial

Free
Zulfa Omer, Alexey Danilov, Francesco Forconi, Talha Munir, Mary Gleeson, Nirav Shah, Graham Collins, Alvaro Alencar, Jane Robertson, Jonathon Cohen, Karan Dixit, Danielle Brander, John Byrd, Allison Winter, Jeffery Smith, Dima El-Sharkawi, Michal Kwiatek, Iwona Hus, Prioty Islam, Sebastian Grosicki, Michael Tees, Thorsten Zenz, Joanna Romejko-Jarosinska, Sarah Injac, Wojciech Jurczak
Journal: Blood
Blood (2025) 146 (Supplement 1): 86.
https://doi.org/10.1182/blood-2025-86
Published: 2025
Journal Articles

Fixed-duration epcoritamab monotherapy induces high response and MRD-negativity rates in elderly patients with newly diagnosed large B-cell lymphoma (LBCL) and comorbidities: Results from EPCORE DLBCL-3

Free
Umberto Vitolo, Johannes Duell, Juan Miguel Bergua Burgues, Wojciech Jurczak, Michal Kwiatek, Marie Maerevoet, Sergio Ortegon Alcaide, David Belada, Won Seog Kim, Richard Greil, Raul Cordoba, Juan-Manuel Sancho, David Sibon, Catherine Thieblemont, Takahiro Kumode, Monica Wielgos-Bonvallet, Tony Jiang, Yanli Wang, Stephanie McGoldrick, Evelyn Guo, Franck Morschhauser, Sherida Woei-A-Jin
Journal: Blood
Blood (2025) 146 (Supplement 1): 63.
https://doi.org/10.1182/blood-2025-63
Published: 2025
Journal Articles

primary Phase 3 results from the epcore FL-1 trial of epcoritamab with rituximab and lenalidomide (R2) versus R2 for relapsed or refractory follicular lymphoma

Free
Lorenzo Falchi, Marcel Nijland, Huiqiang Huang, Kim Linton, John Seymour, Rong Tao, Michal Kwiatek, Abel Costa, Theodoros Vassilakopoulos, Richard Greil, Ana Jiménez Ubieto, Shane Gangatharan, Ohad Benjamini, Catherine Thieblemont, Alessandra Tucci, Anna Elinder-Camburn, Arpad Illes, Jan Novak, Miguel Pavlovsky, Andrew McDonald, Dok Hyun Yoon, Yuko Mishima, Gauri Sunkersett, Jian Mei, Nabanita Mukherjee, Feng Zhu, Elena Favaro, Franck Morschhauser
Journal: Blood
Blood (2025) 146 (Supplement 1): 466.
https://doi.org/10.1182/blood-2025-466
Published: 2025
Journal Articles

An open-label, Phase 2 study of dapolsertib (MEN1703, SEL24) as monotherapy and in combination with glofitamab in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma

Free
Herve Ghesquieres, Malgorzata Krawczyk-Kulis, Dominik Chraniuk, Michal Kwiatek, Hendrik Nogai, Chadi Saba, Adam Falkowski, Katarzyna Kucharz, Michal Kulesza, Ruth Curley, Gary Wilkinson, Przemyslaw Juszczynski, Francesco Bertoni, Daniela Bellarosa, Antonio Galleu, Ira Gupta, Monika Dlugosz-Danecka, Wojciech Jurczak, Guillaume Cartron, Grzegorz Nowakowski
Journal: Blood
Blood (2025) 146 (Supplement 1): 5481.
https://doi.org/10.1182/blood-2025-5481
Published: 2025
Journal Articles

Golseek-1: A Phase 3, double-blind, randomized study of golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, + R-CHOP vs placebo + R-CHOP in patients with previously untreated, high-risk, large B-cell lymphoma

Free
Theodoros Vassilakopoulos, Javier Munoz, Huiqiang Huang, Ichiro Kawashima, Sung Yong Oh, Wojciech Jurczak, Juan Miguel Bergua Burgues, Ou Bai, Alejandro Berkovits, Keshu Zhou, Marc Hoffmann, Jason Westin, Maria Bouzani, Michal Kwiatek, Tai-Chung Huang, Argyrios Gkasiamis, Arpankumar Patel, Floriane Boucaud, Adrien Petel, Serena Perna, Grzegorz Nowakowski
Journal: Blood
Blood (2025) 146 (Supplement 1): 3704.
https://doi.org/10.1182/blood-2025-3704
Published: 2025
Journal Articles

Golseek-1: A Phase 3, Double-Blind, Randomized Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Vs R-CHOP in Patients with Previously Untreated, High-Risk, Large B-Cell Lymphoma

Free
Marc Hoffmann, Theodoros Vassilakopoulos, Javier Munoz, Jason R. Westin, Maria Bouzani, Wojciech Jurczak, Michał Kwiatek, Alejandro Berkovits, Tai-Chung Huang, Akshay Sudhindra, Arpankumar Patel, Floriane Boucaud, Adrien Petel, Grzegorz S. Nowakowski
Journal: Blood
Blood (2024) 144 (Supplement 1): 1742.2.
https://doi.org/10.1182/blood-2024-203185
Published: 2024
Journal Articles

Odronextamab Monotherapy in Previously Untreated Patients with High-Risk Follicular Lymphoma (FL): Results of the Safety Lead-in of the Phase 3 Olympia-1 Study

Free
Elizabeth Brem, Wojciech Jurczak, David Belada, Jaime Perez de Oteyza, Aranzazu Alonso Alonso, Fevzi Altuntas, Michał Kwiatek, Joshua Brody, Ernesto Perez Persona, Mustafa Yenerel, Monica Tani, Jingxian Cai, Priya Deshpande, Saleem Shariff, Aafia Chaudhry, Hesham Mohamed, Srikanth Ambati, Ashish Risal, Ruemu Birhiray
Journal: Blood
Blood (2024) 144 (Supplement 1): 4411.
https://doi.org/10.1182/blood-2024-200080
Published: 2024